Low-density lipoprotein lowering therapy: An analysis of the options

Journal of the American College of Cardiology

Volumn 40, Issue 12, 2002, Pages 2135-2138

  Sacks, Frank M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIETARY FIBER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; GEL; HIGH RISK PATIENT; HUMAN; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; JAUNDICE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; MYOPATHY; MYOSITIS; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TABLET FORMULATION;

EID: 0037132602     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02609-8     Document Type: Editorial

References (36)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344: 1383-9.
2. Simes J, Furberg CD, Braunwald E, et al. Effects of pravastatin on mortality in patients with and without coronary disease across a broad range of cholesterol levels: The Prospective Pravastatin Pooling project. Eur Heart J 2002;23:207-15.
3. Downs JR, Clearfield M, Weis S, et al., for the AFCAPS/Texcaps Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,356 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
5. Byington RP, Davis BR, Plehn JF, et al., for the PPP Investigators. Reduction of stroke events with pravastatin: The Prospective Pravastatin Pooling (PPP) Project. Circulation 2001;103:387-92.
6. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, II: The relationship of reduction of incidence of coronary heart disease to cholesterol lowering. JAMA 1988;260:641-51.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
8. Brown L, Rosner B, Willett WC, Sacks FM. Cholesterol lowering effects of dietary fiber: A meta-analysis. Am J Clin Nutr 1999;69:30-42.
9. Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001;110:352-60.
10. Hunninghake D, Insull W, Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001;158:407-16.
11. Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: Pooled analysis of two Phase II studies. Clin Ther 2001;23:1209-30.
12. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-34.
13. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002;105: 2469-75.
14. Patrick JE, Kosoglou T, Stauber KL, et al. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos 2002;30:430-7.
15. Ezzet F, Wexler D, Statkevich P, et al. The plasma concentration and LDL-C relationship in patients receiving ezetimibe. J Clin Pharmacol 2001;41:943-9.
16. Sudhop T, Lǔtjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106: 1943-8.
17. Pedersen TR, Wilhelmsen L, Faergeman O, et al. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. Am J Cardiol 2000;86:257-62.
18. The LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: The LIPID trial follow-up. Lancet 2002; 359:1379-87.
19. Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials. Prospective Pravastatin Pooling (PPP) Project. Circulation 2002;105:2341-6.
20. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996;275:55-60.
21. Smith GD, Song F, Sheldon TA. Cholesterol lowering and mortality: The importance of considering the initial level of risk. BMJ 1993;306: 1367-73.
22. Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001;84:886-91.
23. Schectman G, Hiatt J. Dose-response characteristics of cholesterol-lowering drug therapies: Implications for treatment. Ann Intern Med 1996;125:990-1000.
24. Goldberg AC. Clinical trial experience with extended-release niacin (Niaspan): Dose-escalation study. Am J Cardiol 1998;82:35U-8U.
25. Karalis DG, Ross AM, Vacari RM, Zarren H, Scott R. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. Am J Cardiol 2002;89:667-71.
26. Schwarz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. JAMA 2001;285:1711-8.
27. MacMahon M, Kirkpatrick C, Cummings CE, et al. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr Metab Cardiovasc Dis 2000;10: 195-203.
28. Cannon CP, McCabe CH, Belder R, Breen J, Braunwald E. Pravastatin or atorvastatin evaluation and infection therapy (PROVE-IT)TIMI 22 Trial: Rationale and design. Am J Cardiol 2002;89:860-1.
29. Kennedy HL, Rosenson RS. Physicians' interpretation of the "class effects"-A need for thoughtful re-evaluation. J Am Coll Cardiol 2002;40:19-26.
30. Jacobson TA. "The lower the better" in hypercholesterolemic therapy: A reliable clinical guideline? Ann Intern Med 2000;133:549-54.
31. Illingworth DR, Crouse JR, Hunninghake DB, et al. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin 2001;17:43-50.
32. Stein EA, Davidson MH, Dobs AS, et al. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. Am J Cardiol 1998;82:311-6.
33. Davidson MH, Stein EA, Hunninghake DB, et al. Lipid-altering efficacy and safety of simvastatin 80 mg/day: Worldwide long-term experience in patients with hypercholesterolemia. Nutr Metab Cardiovasc Dis 2000;10:253-63.
34. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Arch Intern Med 1991;151:43-9.
35. Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safety profile of atorvastatin. Arch Intern Med 1998;158:577-84.
36. Pasternak RC, Smith SC Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567-72.